Conference Track

New Agents and Insights from Basic Science

Source: CCO Official Conference Coverage of the 2006 International AIDS Conference

Capsule Summaries

HIV-1 Resistance to CCR5 Inhibitors Can Involve the Use of Inhibitor-CCR5 Complex for Cell Entry
Clinical HIV-1 Isolates Retain Greater Susceptibility to Brecanavir vs Other PIs Despite Presence of Multiple PI Resistance Mutations
Potent Activity of Integrase Inhibitor MK-0518 in Treatment-Naive HIV-Infected Adults
Maraviroc Safe in Treatment-Experienced Patients With Detectable X4 HIV-1, Despite Lack of Virologic Efficacy
Sustained-Release Formulations of Next-Generation Fusion Inhibitors Display Promising Pharmacokinetics in Preclinical Studies
PPL-100, a Novel PI, Demonstrates Promising Pharmacokinetics, in Vitro Activity Against PI-Resistant HIV
Single-Dose Study Suggests Fosalvudine Tidoxil Safe and Tolerable, With Potential for Once-Daily Dosing in HIV-Infected Patients
Vicriviroc Plus Optimized Background Regimen Significantly Reduced HIV-1 RNA at 24 Weeks in Treatment-Experienced Patients With R5-Tropic HIV
Next-Generation Fusion Inhibitors TRI-999 and TRI-1144 Active in Vitro Against HIV-1 Resistant to Enfuvirtide
TNX-355 Produces Durable Virologic and Immunologic Benefit in Heavily Treatment-Experienced HIV Patients

Expert Analysis

New Agents and Insights from Basic Science

Faculty:

Pedro Cahn, MD, PhD
Joseph J. Eron, Jr., MD
Daniel R. Kuritzkes, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount data on the safety and efficacy of novel agents such as CCR5 inhibitors, entry inhibitors, and integrase inhibitors as therapy for treatment-experienced or treatment-naive HIV patients
Summarize new data on the use of novel therapies in the setting of resistant HIV
Describe the in vitro activity of novel therapies in the HIV setting, including novel PIs and fusion inhibitors

CME CREDIT INFORMATION

Release Date: 10/06/06

Expiration Date: 10/05/07

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing CE credits

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.